Schedule of Investments
ARK Genomic Revolution ETF
April 30, 2026 (Unaudited)
| Investments | Shares | Value | ||||||
| COMMON STOCKS–99.6% | ||||||||
| Biotechnology - 57.0% | ||||||||
| Absci Corp.*†(a) | 11,876,202 | $ | 59,084,105 | |||||
| Arcturus Therapeutics Holdings, Inc.*†(a) | 2,809,043 | 24,213,950 | ||||||
| Beam Therapeutics, Inc.* | 2,212,153 | 67,094,600 | ||||||
| BioNTech SE (Germany)*(b) | 126,929 | 13,130,805 | ||||||
| CareDx, Inc.* | 2,009,757 | 41,823,043 | ||||||
| Compass Pathways PLC (United Kingdom)*(b) | 3,316,076 | 30,043,649 | ||||||
| CRISPR Therapeutics AG (Switzerland)*(a) | 2,103,707 | 110,108,024 | ||||||
| Generate BioMedicines, Inc.* | 503,531 | 6,359,597 | ||||||
| Intellia Therapeutics, Inc.*(a) | 3,498,399 | 47,158,418 | ||||||
| Ionis Pharmaceuticals, Inc.* | 288,230 | 21,548,075 | ||||||
| Natera, Inc.* | 243,718 | 50,244,903 | ||||||
| Nurix Therapeutics, Inc.* | 1,723,734 | 28,786,358 | ||||||
| Prime Medicine, Inc.* | 4,925,864 | 17,462,188 | ||||||
| Recursion Pharmaceuticals, Inc., Class A*(a) | 12,549,240 | 43,420,370 | ||||||
| Twist Bioscience Corp.* | 1,900,539 | 111,086,505 | ||||||
| Veracyte, Inc.* | 999,975 | 32,919,177 | ||||||
| Total Biotechnology | 704,483,767 | |||||||
| Electronic Equipment, Instruments & Components - 1.1% | ||||||||
| 908 Devices, Inc.*† | 1,952,552 | 13,335,930 | ||||||
| Health Care Equipment & Supplies - 3.1% | ||||||||
| Butterfly Network, Inc.*(a) | 4,889,029 | 23,418,449 | ||||||
| Cerus Corp.* | 7,450,534 | 15,124,584 | ||||||
| Total Health Care Equipment & Supplies | 38,543,033 | |||||||
| Health Care Providers & Services - 5.6% | ||||||||
| GeneDx Holdings Corp.* | 401,292 | 25,237,254 | ||||||
| Guardant Health, Inc.* | 496,000 | 43,191,680 | ||||||
| Total Health Care Providers & Services | 68,428,934 | |||||||
| Health Care Technology - 2.0% | ||||||||
| Schrodinger, Inc.* | 2,093,199 | 25,034,660 | ||||||
| Life Sciences Tools & Services - 28.4% | ||||||||
| 10X Genomics, Inc., Class A* | 3,232,541 | 71,277,529 | ||||||
| Adaptive Biotechnologies Corp.* | 2,123,561 | 29,942,210 | ||||||
| Alamar Biosciences, Inc.*(a) | 596,585 | 14,938,489 | ||||||
| Illumina, Inc.* | 392,835 | 49,787,908 | ||||||
| Pacific Biosciences of California, Inc.* | 10,964,895 | 17,434,183 | ||||||
| Personalis, Inc.*† | 8,017,242 | 44,255,176 | ||||||
| Quantum-Si, Inc.*(a) | 6,928,343 | 6,793,933 | ||||||
| Tempus AI, Inc.*(a) | 2,098,455 | 116,422,283 | ||||||
| Total Life Sciences Tools & Services | 350,851,711 | |||||||
| Pharmaceuticals - 2.4% | ||||||||
| AtaiBeckley, Inc. (Germany)* | 4,382,604 | 18,231,633 | ||||||
| Eli Lilly & Co. | 12,571 | 11,748,856 | ||||||
| Total Pharmaceuticals | 29,980,489 | |||||||
| Total Common Stocks | ||||||||
| (Cost $2,614,311,648) | 1,230,658,524 | |||||||
| Investments | Shares | Value | ||||||
| MONEY MARKET FUND–0.1% | ||||||||
| Goldman Sachs Financial Square Treasury Obligations Fund, 3.54% (c) | ||||||||
| (Cost $1,581,573) | 1,581,573 | $ | 1,581,573 | |||||
| Total Investments–99.7% | ||||||||
| (Cost $2,615,893,221) | 1,232,240,097 | |||||||
| Other Assets in Excess of Liabilities–0.3% | 3,632,208 | |||||||
| Net Assets–100.0% | $ | 1,235,872,305 |
| (a) | All or a portion of the security was on loan. The aggregate market value of the securities on loan was $157,344,717; total market value of the collateral held by the fund was $149,290,355.The total market value of the collateral includes non-cash U.S. Treasury securities collateral having a value of $149,290,355. |
| † | Affiliated security |
| * | Non-income producing security |
| (b) | American Depositary Receipt |
| (c) | Rate shown represents annualized 7-day yield as of April 30, 2026. |
Schedule of Investments (continued)
ARK Genomic Revolution ETF
April 30, 2026 (Unaudited)
Affiliated Issuer Transactions
An affiliated company is a company in which the Fund has ownership of at least 5% of the voting securities, or a company that is under common ownership or control. Period-to-date transactions with companies which are or were affiliates are as follows:
| Value ($) at 7/31/2025(a) | Purchases Cost ($) | Sales Proceeds ($) | Net Realized Gain/(Loss) on investments in affiliated securities ($) | Net Change in Unrealized Appreciation (Depreciation) on investments in affiliated securities ($) | Net Change in Unrealized Appreciation (Depreciation) on investments in non-affiliated securities ($) | Affiliated Dividend Income ($) | Capital Gain Distributions ($) | Number of Shares at 4/30/2026 | Value ($) at 4/30/2026(a) | |||||||||||||||||||||||||||||||
| Common Stocks — 11.4% | ||||||||||||||||||||||||||||||||||||||||
| Biotechnology — 6.7% | ||||||||||||||||||||||||||||||||||||||||
| Absci Corp. | ||||||||||||||||||||||||||||||||||||||||
| 33,212,741 | 49,408,090 | (45,558,687 | ) | 771,774 | 21,250,187 | – | – | – | 11,876,202 | 59,084,105 | ||||||||||||||||||||||||||||||
| Arcturus Therapeutics Holdings, Inc. | ||||||||||||||||||||||||||||||||||||||||
| 20,607,391 | 41,450,786 | (28,007,344 | ) | 556,445 | (10,393,328 | ) | – | – | – | 2,809,043 | 24,213,950 | |||||||||||||||||||||||||||||
| Electronic Equipment, Instruments & Components — 1.1% | ||||||||||||||||||||||||||||||||||||||||
| 908 Devices, Inc. | ||||||||||||||||||||||||||||||||||||||||
| 14,371,630 | 16,218,179 | (17,431,703 | ) | (10,244,915 | ) | 10,422,739 | – | – | – | 1,952,552 | 13,335,930 | |||||||||||||||||||||||||||||
| Life Sciences Tools & Services — 3.6% | ||||||||||||||||||||||||||||||||||||||||
| Personalis, Inc. | ||||||||||||||||||||||||||||||||||||||||
| 38,378,556 | 87,151,810 | (81,311,198 | ) | (4,038,234 | ) | 4,074,242 | – | – | – | 8,017,242 | 44,255,176 | |||||||||||||||||||||||||||||
| $ | 106,570,318 | $ | 194,228,865 | $ | (172,308,932 | ) | $ | (12,954,930 | ) | $ | 25,353,840 | $ | – | $ | – | $ | – | 24,655,039 | $ | 140,889,161 | ||||||||||||||||||||
| (a) | The fair value and number of shares of securities are only displayed at the beginning and end of each reporting period when such securities were considered an affiliate as of each date. Refer to the Schedule of Investments for view the fair value and number of shares as of April 30, 2026. |
Fair Value Measurement
The Fund discloses the fair value of its investments in a hierarchy that distinguishes between: (i) market participant assumptions
developed based on market data obtained from sources independent of the Fund (observable inputs) and (ii) the Fund’s own assumptions
about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs).
The three levels defined by the hierarchy are as follows:
• Level 1 — Quoted prices in active markets for identical assets.
• Level 2 — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).
• Level 3 — Significant unobservable inputs (including each Fund’s own assumptions in determining the fair value of investments).
The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.
The following is a summary of the valuations as of April 30, 2026, based upon the three levels defined above:
| ARK Genomic Revolution ETF | Level 1 | Level 2 | Level 3 | Total | ||||||||||||
| Assets | ||||||||||||||||
| Common Stocks‡ | $ | 1,230,658,524 | $ | – | $ | – | $ | 1,230,658,524 | ||||||||
| Money Market Fund | 1,581,573 | – | – | 1,581,573 | ||||||||||||
| Total | $ | 1,232,240,097 | $ | – | $ | – | $ | 1,232,240,097 | ||||||||
| ‡ | Please refer to the Schedule of Investments to view securities segregated by industry type. |